Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Contraception

Conditions

Contraception

Trial Timeline

Feb 1, 2003 → Oct 1, 2005

About Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg

Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg is a phase 3 stage product being developed by Pfizer for Contraception. The current trial status is completed. This product is registered under clinical trial identifier NCT00245921. Target conditions include Contraception.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00245921Phase 3Completed

Competing Products

20 competing products in Contraception

See all competitors
ProductCompanyStageHype Score
Injection CyclofemSun PharmaceuticalPhase 1/2
41
Relugolix Combination TherapySumitomo PharmaPhase 3
77
Transdermal Contraceptive System + Norgestimate-containing oral contraceptives with EEJohnson & JohnsonPre-clinical
23
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.Johnson & JohnsonPhase 1
33
norelgestromin + ethinyl estradiolJohnson & JohnsonPhase 3
77
norelgestromin + ethinyl estradiol; triphasil.Johnson & JohnsonPhase 3
77
norelgestromin + ethinyl estradiol; mercilonJohnson & JohnsonPhase 3
77
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
33
EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EEJohnson & JohnsonPhase 1
33
Monophasic or triphasic Oral contraceptive tablet + Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EEJohnson & JohnsonPre-clinical
23
Norgestimate/Ehinyl Estradiol; Folic acid.Johnson & JohnsonPhase 1
33
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
33
oral ulipristal acetateMerckPhase 1
33
Etonogestrel contraceptive implantMerckApproved
85
Rifampin 600 MGMerckApproved
85
Long Acting Reversible Contraception (LARC)MerckApproved
85
Etonogestrel contraceptive implantMerckApproved
85
Medroxyprogesterone 17-Acetate + Medroxyprogesterone 17-AcetatePfizerPre-clinical
22
Sayana PressPfizerApproved
84
Depo-Provera Contraceptive Injection - DP150CIPfizerApproved
84